Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLUES-UC-J: Mirikizumab in Ulcerative Colitis in Japan
jRCT1031250127Active, not recruiting
- Sponsor
- Kitasato University
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of mirikizumab in autoimmune colitis, sponsored by Kitasato University. Primary endpoint: Symptomatic remission at Week 52. Started Jun 2025; status: active, not recruiting.
02
Drugs
mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT1031250127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031250127.